Hester Biosciences
Healthcare
HESTERBIO NSE
₹2,312.00 +49.90 (+2.21%)
- P/E
- Not meaningful: last twelve months’ earnings are mostly a one-off item
Close 4 Nov 2026 ₹2,312.00 +720.60 +45.3% 1Y
Start ₹1,591.40
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 15.20%
- Debt to Equity
- 0.54
- EPS (TTM)
- ₹160.08
- Book Value
- ₹423.46
- Market Cap
- —
- P/E (TTM)
- Not meaningful: last twelve months’ earnings are mostly a one-off item
- P/B
- 5.46
- ROE
- 15.90%
- Dividend Yield
- 0.49%
- EBITDA
- ₹96.30 Cr
- 52W High
- ₹2,683.60
- 52W Low
- ₹1,239.30
- Day Range
- ₹2,259.60 – ₹2,324.00
- Volume
- 1,816
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Hester Biosciences (this company) | ₹2,312.00 | — | ₹1,939 Cr | 5.46 | 0.49% | 15.90% | 15.20% | ₹326 Cr | ₹137 Cr |
| Median 8 companies | ₹2,042.70 | 38.81 | ₹1,25,337 Cr | 5.12 | 0.53% | 16.25% | 16.65% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
55 Good
Data confidence 100/100
Category scores
- Quality
- 62
- Good
- Returns, margins, earnings quality 22% weight
- Valuation
- 76
- Strong
- Cheap vs sector & own history 24% weight
- Growth
- 19
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 47
- Average
- Solvency, leverage, coverage 9% weight
- Momentum
- 69
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 38
- Weak
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company has been maintaining a healthy dividend payout of 21.8%
- Company's working capital requirements have reduced from 80.2 days to 54.4 days
Weaknesses
5- Stock is trading at 4.89 times its book value
- The company has delivered a poor sales growth of 9.19% over past five years.
- Company has a low return on equity of 10.8% over last 3 years.
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.105 Cr.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 2 | 5 | 12 |
| Oscillators | Neutral | 2 | 5 | 2 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Neutral
Bearish
2
Neutral
5
Bullish
2
Overall
Strong Bullish
Bearish
2
Neutral
5
Bullish
12
Moving Averages
Strong Bullish
Bearish
0
Neutral
0
Bullish
10
Key readings
- RSI (14)
- 59.08
- Neutral
- MACD (12,26,9)
- 21.19
- Bullish
- SMA (50)
- 2,217.72
- Bullish
- SMA (200)
- 1,927.98
- Bullish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +12.67% |
|---|---|
| 5Y | +9.25% |
| 3Y | +7.78% |
| 1Y | +7.07% |
| TTM | +3.83% |
Net profit
| 10Y | +11.61% |
|---|---|
| 5Y | +10.25% |
| 3Y | +26.74% |
| 1Y | +96.55% |
| TTM | +260.53% |
Operating cash flow
| 10Y | +12.91% |
|---|---|
| 5Y | +1.99% |
| 3Y | +38.67% |
| 1Y | −1.54% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | −7.53 pp |
|---|---|
| 5Y | −6.11 pp |
| 3Y | +6.96 pp |
| 1Y | +6.19 pp |
| TTM | +5.68 pp |
Revenue by year
| Mar 2017 | ₹123 Cr |
|---|---|
| Mar 2018 | ₹136 Cr |
| Mar 2019 | ₹178 Cr |
| Mar 2020 | ₹183 Cr |
| Mar 2021 | ₹214 Cr |
| Mar 2022 | ₹235 Cr |
| Mar 2023 | ₹266 Cr |
| Mar 2024 | ₹305 Cr |
| Mar 2025 | ₹311 Cr |
| Mar 2026 | ₹333 Cr |
Net profit by year
| Mar 2017 | ₹23.00 Cr |
|---|---|
| Mar 2018 | ₹23.00 Cr |
| Mar 2019 | ₹41.00 Cr |
| Mar 2020 | ₹31.00 Cr |
| Mar 2021 | ₹35.00 Cr |
| Mar 2022 | ₹39.00 Cr |
| Mar 2023 | ₹28.00 Cr |
| Mar 2024 | ₹21.00 Cr |
| Mar 2025 | ₹29.00 Cr |
| Mar 2026 | ₹57.00 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 88 | 70 | 67 | 79 | 82 | 84 | 63 | 82 | 84 | 71 | 77 | 100 | 77 |
| Expenses | 73 | 57 | 57 | 63 | 65 | 65 | 58 | 63 | 61 | 59 | 60 | 66 | 54 |
| Operating Profit | 14 | 13 | 10 | 16 | 18 | 19 | 5 | 19 | 23 | 12 | 18 | 34 | 23 |
| OPM % | 16% | 19% | 15% | 20% | 21% | 23% | 8% | 23% | 27% | 17% | 23% | 34% | 29% |
| Other Income | 1.15 | 4.36 | 0.99 | 4.15 | 1.23 | 1.84 | 7.81 | −6.95 | 2.32 | 9.73 | 0.67 | 2 | 89 |
| Interest | 3 | 8 | 2 | 7 | 5 | 6 | −4 | 6 | 2 | 2 | 2 | 5 | 3 |
| Depreciation | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 6 | 7 |
| PBT | 9 | 7 | 6 | 9.39 | 9.73 | 10.91 | 12.39 | 4 | 19.14 | 17 | 14 | 25 | 102 |
| Tax % | 25% | 40% | 37% | 35% | 29% | 29% | 15% | 59% | 14% | 16% | 31% | 34% | 5% |
| Net Profit | 7 | 4 | 4 | 6 | 7 | 8 | 11 | 2 | 17 | 14 | 9 | 17 | 97 |
| EPS (₹) | 6.9 | 4.81 | 4.68 | 5.82 | 7.45 | 9.64 | 13.71 | 1.52 | 19.33 | 16.99 | 10.31 | 18.78 | 114 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 90 | 101 | 123 | 136 | 178 | 183 | 214 | 235 | 266 | 305 | 311 | 333 | 326 |
| Expenses | 64 | 67 | 82 | 89 | 110 | 128 | 146 | 175 | 215 | 251 | 250 | 246 | 239 |
| Operating Profit | 25 | 34 | 41 | 47 | 68 | 55 | 69 | 60 | 51 | 54 | 62 | 87 | 87 |
| OPM % | 28% | 34% | 33% | 35% | 38% | 30% | 32% | 26% | 19% | 18% | 20% | 26% | 27% |
| Other Income | 3 | 1 | 0 | 3 | 7 | 6 | 1 | 14 | 20 | 15 | 8 | 19 | 105 |
| Interest | 5 | 4 | 4 | 4 | 7 | 7 | 7 | 4 | 9 | 20 | 13 | 11 | 12 |
| Depreciation | 6 | 6 | 7 | 10 | 12 | 13 | 13 | 17 | 21 | 17 | 17 | 19 | 22 |
| PBT | 18 | 25 | 31 | 36 | 57 | 41 | 50 | 54 | 40 | 32 | 40 | 76 | 157 |
| Tax % | 26% | 23% | 26% | 36% | 28% | 25% | 31% | 26% | 30% | 34% | 27% | 24% | — |
| Net Profit | 13 | 19 | 23 | 23 | 41 | 31 | 35 | 39 | 28 | 21 | 29 | 57 | 137 |
| EPS (₹) | 15.99 | 22.57 | 27.68 | 30.12 | 48.87 | 34.29 | 40.47 | 46.22 | 31.3 | 22.21 | 32.31 | 65.41 | 160 |
| Div. Payout % | 19% | 18% | 19% | 33% | 23% | 19% | 25% | 22% | 26% | 27% | 22% | 17% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Reserves | 76 | 93 | 113 | 132 | 169 | 193 | 220 | 251 | 271 | 283 | 306 | 352 |
| Borrowings | 55 | 59 | 66 | 69 | 90 | 121 | 105 | 228 | 274 | 244 | 213 | 195 |
| Other Liabilities | 20 | 25 | 25 | 35 | 32 | 65 | 78 | 74 | 116 | 126 | 126 | 123 |
| Total Liabilities | 160 | 186 | 213 | 244 | 299 | 387 | 411 | 562 | 670 | 662 | 653 | 678 |
| Fixed Assets | 60 | 65 | 102 | 110 | 145 | 143 | 133 | 237 | 259 | 240 | 233 | 411 |
| CWIP | 33 | 36 | 21 | 32 | 7 | 74 | 109 | 82 | 149 | 171 | 183 | 9 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 25 | 30 | 34 | 43 |
| Other Assets | 68 | 85 | 89 | 102 | 148 | 170 | 169 | 222 | 237 | 221 | 203 | 215 |
| Total Assets | 160 | 186 | 213 | 244 | 299 | 387 | 411 | 562 | 670 | 662 | 653 | 678 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 20 | 19 | 35 | 38 | 47 | 37 | 58 | 9 | 24 | 48 | 65 | 64 |
| Investing | −21 | −13 | −30 | −26 | −21 | −73 | −42 | −117 | −77 | −22 | −20 | −18 |
| Financing | 7 | −7 | 2 | −11 | 3 | 19 | −18 | 112 | 42 | −26 | −52 | −49 |
| Net Cash Flow | 5 | −1 | 6 | 1 | 28 | −17 | −2 | 3 | −12 | 0 | −7 | −3 |
| Free Cash Flow | 1 | 5 | 5 | 15 | 24 | −36 | 17 | −87 | −54 | 24 | 44 | 47 |
| CFO/OP | 100 | 74 | 102 | 100 | 92 | 86 | 105 | 43 | 63 | 112 | 123 | 90 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 72 | 95 | 79 | 87 | 67 | 116 | 84 | 86 | 109 | 94 | 86 | 105 |
| Inventory Days | 431 | 627 | 376 | 505 | 540 | 834 | 452 | 424 | 399 | 288 | 291 | 323 |
| Days Payable | 68 | 109 | 84 | 100 | 93 | 261 | 204 | 101 | 141 | 98 | 122 | 110 |
| Cash Conversion Cycle | 434 | 614 | 371 | 491 | 514 | 690 | 332 | 409 | 367 | 284 | 255 | 318 |
| Working Capital Days | 76 | 112 | 90 | 82 | 106 | 104 | 134 | 113 | 88 | 112 | 74 | 54 |
| ROCE % | 15% | 19% | 19% | 20% | 26% | 16% | 18% | 14% | 9% | 9% | 10% | 15% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Hester Biosciences insights
72 extracted metrics across FY11–FY27.
Documents
- Q1 FY27 concall · Aug 2026Transcript Recording
- Concall · Jul 2026Recording
- Concall · May 2026Transcript PPT Recording
- Q3 FY26 concall · Jan 2026Transcript Recording
- Concall · Nov 2025Transcript
- 1 Aug 2025
- 7 Sep 2026
- 23 Mar 2026
- 27 Dec 2024
- 5 Jan 2024
- 7 Jul 2023
- General announcements 28 Oct 2026
- General announcements 27 Oct 2026
- General announcements 14 Oct 2026
Frequently Asked Questions about Hester Biosciences
What does Hester Biosciences Ltd do?
Incorporated in 1987, Hester Biosciences Ltd is one of India’s leading animal healthcare companies and a major manufacturer of poultry and animal vaccines, including a leading position in PPR and Goat Pox vaccines.
Where is Hester Biosciences Ltd (HESTERBIO) listed?
Hester Biosciences Ltd trades as HESTERBIO on the NSE and under code 524669 on the BSE.
Which sector does Hester Biosciences Ltd belong to?
Hester Biosciences Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Hester Biosciences Ltd?
Over the last 52 weeks Hester Biosciences Ltd has traded between ₹1,239.3 and ₹2,683.6 as of 4 Nov 2026.
Does Hester Biosciences Ltd pay dividends?
Hester Biosciences Ltd has a dividend yield of 0.49%.
What is the Return on Equity (ROE) of Hester Biosciences Ltd?
Hester Biosciences Ltd reported a return on equity of 15.90%. Its debt-to-equity ratio is 0.54.
Company Information
Incorporated in 1987, Hester Biosciences Ltd is one of India’s leading animal healthcare companies and a major manufacturer of poultry and animal vaccines, including a leading position in PPR and Goat Pox vaccines.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/HESTERBIO.md for Hester Biosciences Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.